Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials

Published:2024-05-13 Issue: Volume: Page:
ISSN:1559-0100
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Deng Bixin,Ruan Tiechao,Lu Wenting,Ying Junjie,Li Shiping,Zhou Ruixi,Mu Dezhi

Funder

National Natural Science Foundation of China

Clinical research Special Fund of Wu Jieping Medical Foundation

National Key R&D Program of China

Fundamental Research Funds for Central Universities of the Central South University

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12020-024-03857-6.pdf

Reference51 articles.

1. H. Sun, P. Saeedi, S. Karuranga, M. Pinkepank, K. Ogurtsova et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119 (2022)

2. WHO, Obesity. (2024) https://www.who.int/health-topics/obesity#tab=tab_1

3. X.-F. Pan, L. Wang, A. Pan, Epidemiology and determinants of obesity in China. Lancet Diabetes Endocrinol. 9, 373–392 (2021)

4. E. Ahmad, S. Lim, R. Lamptey, D.R. Webb, M.J. Davies, Type 2 diabetes. Lancet 400, 1803–1820 (2022)

5. L. Perreault, J.S. Skyler, J. Rosenstock, Novel therapies with precision mechanisms for type 2 diabetes mellitus. Nat. Rev. Endocrinol. 17, 364–377 (2021)

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy;International Journal of Molecular Sciences;2024-07-27